falnidamol
Term · Oncology and biomedicine · MLC-T-ONC-013521
A pyrimido-pyrimidine with antitumor activity. BIBX 1382 inhibits the intracellular tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) thus specifically reversing the aberrant enzymatic activity from overexpressed and constitutively activated EGFR, and subsequently inhibiting cell proliferation and inducing cell differentiation.
| Identifier | MLC-T-ONC-013521 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | EGFR inhibitor BIBX 1382 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013521",
"term": "falnidamol",
"field": "Oncology and biomedicine",
"definition": "A pyrimido-pyrimidine with antitumor activity. BIBX 1382 inhibits the intracellular tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) thus specifically reversing the aberrant enzymatic activity from overexpressed and constitutively activated EGFR, and subsequently inhibiting cell proliferation and inducing cell differentiation.",
"synonyms": [
"EGFR inhibitor BIBX 1382"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/falnidamol/"
}
Record 7,124 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.